PMID- 36468814
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230320
IS  - 1099-0461 (Electronic)
IS  - 1095-6670 (Linking)
VI  - 37
IP  - 3
DP  - 2023 Mar
TI  - Fingolimod attenuates ovalbumin-induced airway inflammation via inhibiting 
      MAPK/ERK signaling in mice.
PG  - e23266
LID - 10.1002/jbt.23266 [doi]
AB  - The current study was designed to investigate the potential anti-inflammatory and 
      antioxidant effects of fingolimod against Ovalbumin (Ova)-induced allergic airway 
      inflammation compared to dexamethasone. Fingolimod was given (0.5 mg/kg/day, 
      p.o.) for sensitized mice 1 h before Ova challenge from Days 19 to 24. Fingolimod 
      significantly inhibited Ova-induced elevation of inflammatory cells and 
      eosinophils numbers in bronchoalveolar lavage fluid (BALF) and reduced 
      concentrations of immunoglobulin E in serum and of sphingosine-1-phosphate, 
      interleukin (IL)-4, and IL-13 in BALF. Fingolimod inhibited microvascular leakage 
      and edema as reflected by the decreased lung/body weight index. These findings 
      were supported by histopathological examination results showing that fingolimod 
      substantially decreased perivascular edema and inflammatory cell infiltration. 
      Fingolimod also attenuated Ova-induced oxidative stress as evidenced by decreased 
      malondialdehyde concentration along with increasing concentrations of reduced 
      glutathione and superoxide dismutase in lung tissues. Fingolimod also 
      significantly decreased monocyte chemoattractant protein-1 (MCP-1), p-ERK, and 
      p-P38 in lung tissues of Ova-challenged mice. In conclusion, the current study 
      demonstrated the anti-inflammatory and antioxidant effects of fingolimod in 
      allergic airway inflammation that might be associated with the downregulation of 
      mitogen activated kinases signaling to decrease T helper 2 cytokine secretion 
      (IL-4 and IL-13) and MCP-1 expression, along with the inhibition of oxidative 
      stress.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Makled, Mirhan N
AU  - Makled MN
AUID- ORCID: 0000-0002-2981-6324
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, Mansoura, Egypt.
FAU - El-Sheakh, Ahmed R
AU  - El-Sheakh AR
AUID- ORCID: 0000-0003-2745-3811
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura 
      University, Mansoura, Egypt.
AD  - Future Studies and Risks Management & National Committee of Drugs, Academy of 
      Scientific Research, Ministry of Higher Education, ElSayeda Zeinab, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20221205
PL  - United States
TA  - J Biochem Mol Toxicol
JT  - Journal of biochemical and molecular toxicology
JID - 9717231
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Cytokines)
RN  - G926EC510T (Fingolimod Hydrochloride)
RN  - 0 (Interleukin-13)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Antioxidants/metabolism
MH  - *Asthma
MH  - Bronchoalveolar Lavage Fluid
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Fingolimod Hydrochloride
MH  - Inflammation/metabolism
MH  - Interleukin-13
MH  - Lung/metabolism
MH  - Mice, Inbred BALB C
MH  - Ovalbumin
MH  - MAP Kinase Signaling System
OTO - NOTNLM
OT  - allergic airway inflammation
OT  - fingolimod
OT  - interleukins
OT  - p-ERK
OT  - p38 MAPK
EDAT- 2022/12/06 06:00
MHDA- 2023/03/15 06:00
CRDT- 2022/12/05 08:42
PHST- 2022/10/06 00:00 [revised]
PHST- 2022/04/12 00:00 [received]
PHST- 2022/11/15 00:00 [accepted]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2022/12/05 08:42 [entrez]
AID - 10.1002/jbt.23266 [doi]
PST - ppublish
SO  - J Biochem Mol Toxicol. 2023 Mar;37(3):e23266. doi: 10.1002/jbt.23266. Epub 2022 
      Dec 5.